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Recurrent glioblastoma multiforme focus of clinical trial

Malignant brain tumors a new target
for gene therapy
Lab to clinic

W. K. Alfred Yung is
Deputy Chairman of the
Department of NeuroOncology

Raymond Sawaya is
Chairman of the Depart-

The progno is for patients with gliobla toma therapy. Working together on the tudy are a
multiforme, the most malignant of the primary multidi ciplinary team of n uro -oncologi t ,
brain tumors, is poor. Few patients with gliobla - neuro urgeon , and neuroradiologi t . Ra mond
toma multiforme will be alive five year after the Sawaya, M.D., Chairman of th Department of
tumor is diagnosed. Standard therapies can temeurosurgery, elaborated on the current therap .
porarily shrink the tumor, relieving the intracranial "In some patients, surgery i not po ible. When
pressure and its symptoms-headache, confusion, we do operate, we can u ual1 remo e the tumor,
seizures, and loss of mental function. But patients but even then we ha e not cured the patient,
who undergo these treatments, which include surbecause many microscopic tumor cells remain.
gery, radiotherapy, and chemotherapy, may face Nor does radiotherapy actually kill the tumor cells.
uncomfortable complications or prolonged hospi- The tumors are stopped for a while, but they soon
talization. A new experimental treatment being start growing again. This is why we are looking for
offered patients with recurrent glioblastoma mulinnovative alternative therapies."
tiforme at The University of Texas M. D. Anderson Cancer Center may give hope for a longer or Therapy forces cells to kill themselves
Unlike gene therapies that correct a genetic
more comfortable life . The new treatment is called
aberration responsible for the cancer, the uicide
suicide gene therapy, and although it is experimental, the poor outcomes of current therapy for gene strategy in ol es a gene that ha nothing to
do with human cancer, the Herpes simplex th miglioblastoma multiforme warrant its use.
"Glioblastoma multiforme poses a special clini- dine kina e gene. If proper! in erted into human
cal challenge," said W. K. Alfred Yung, M.D., cancer cells, the gene change the D
of the cell
Deputy Chairman of the Department of euro- so that the become susceptible to the anti iral
Oncology. "Although these tumors rarely metas- drug ganciclovir.
tasize to other parts of the body, they spread
To be effecti e, the suicide gene approach has
throughout the brain very widely, and the tumor to induce the patient's tumor cells to express the
boundaries are often indistinct. The standard treatH. simplex gene. The glioblastoma multiforme
ments may eradicate or reduce the mass, but inevi- trial uses a retrovirus to introduce the gene into
tably some of the remote tumor cells that have the cells, taking advantage of the retrovirus's prosprea
om e mam tumor escape e erapy.
pensity to ec v1 ng ce s. ir
These residual tumor cells grow into new tumors: is altered so it cannot replicate, and then the
thymidine kinase gene is inserted into the retroviof the 11,000 to 12,000 patients treated for glioblastoma multiforme in the United States each rus. The retrovirus is inserted into mouse fibroyear, most of them adults over the age of 50, blast carriers, which are then suspended in a solution
nearly all will have a recurrence within a year after and injected into the tumor. Once inside the tumor,
the fibroblasts divide and produce retroviruses,
treatment of their first tumor.
Yung is principal investigator at M. D. Ander- which infect the tumor cells, incorporating the
son for a multicenter clinical trial of suicide gene thymidine kinase gene into the cell D A.
continued on page 2
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This approach has been used safely in human
studies. The researchers expect that the gene
therapy will reduce the size of the tumors with few
of the side effects or discomforts of standard therapies. Because the fibroblasts come from mice,
however, they may cause immune reactions in
humans. The trial will measure both the effectiveness and the side effects of the gene constructs. To
prevent exposure of normal noncancerous tissues
to these constructs, the constructs are introduced
directly into the tumors by a long needle.
Stereotactic techniques pinpoint tumor
location
When an M. D. Anderson patient with inoperable, recurrent glioblastoma multiforme is
identified and agrees to take part in the study, the
neurosurgeon (usually Sawaya or Ian McCutcheon,
M.D.) and neuroradiologist use stereotactic techniques to locate the tumor precisely in the brain.
Stereotactic techniques were originally developed
as a way of taking biopsies from the brain without
opening the skull. The procedure is safe and widely
used for performing biopsies, draining cysts, placing catheters, and administering drugs directly
into the brain.
Sawaya recounted the procedure: "First, an
external frame is positioned and securely fastened
on the patient's head; this is used as a reference to
pinpoint the location of the tumor in the brain.
Then a computed tomographic ( CT) or magnetic
resonance (MRI) scan of the brain shows the exact
location of the tumor, including its margins, relative to the frame and calculates the optimal entry

Drs. Ian Mccutcheon and David Eng administer the therapeutic gene
construct directly into a patient's brain.

site. The frame serves as a means of guiding the
needle to this site." In the operating room, the site
is prepared for the insertion of the needle through
which the gene constructs are injected. "Only
local anesthesia is used for the entire procedurethere is no pain," continued Sawaya. "The beauty
of this technique is that we know with certainty
exactly where the tumor is without having to open
the skull."
Fourteen days after this treatment, the patient
returns to the hospital for a 14-day course of
ganciclovir. That is the end of the treatment. After
that, said Yung, "we monitor the patient's condition and the size of the tumor. About 30 patients
have been treated on the study so far, only one of
them at M. D. Anderson. That patient had some
side effects, which were probably a reaction to a
slight expansion of the brain caused by the introduction of the viral producer cells, a volume of
approximately 10 milliliters. T he effects resolved
quickly, and we are now waiting to see the patient's
response."
Goal: local control with fewer side effects
An early pilot study in about 15 patients showed
that the suicide gene therapy concept is feasible. A
private company now manufactures the gene constructs and is sponsoring the trial.
Will suicide gene therapy cure these "incurable" tumors? Probably not, said Sawaya. The
ganciclovir will probably kill a portion of the tumor cells, but the residual cells will grow into
another mass. "What we are offering," he explained, "is an alternative that we expect will have
an effect similar to that of the standard therapies,
shrinking the tumor, buying some time for the
patient. The advantage of gene therapy, we hope,
is that the patient will be more comfortable and
feel better."

Research focusing on refinements
Yun and his collea ues have been conducting-------,
research in their laboratory that will allow them to
try other gene therapy strategies in glioblastoma
multiforme. One of these is the introduction of
the normal (wild-type) p53tumor suppressor gene
into the tumor cells, whose mutated form allows
tumor growth. However, the biggest barrier to
cancer gene therapy right now is not the gene
used, but the method used to deliver the gene into
the cancer cells.
Many of the trials now on the drawing board
will use an adenovirus rather than a retrovirus to
introduce the gene. Although retroviruses were
continued on page 5
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Informed patients make better decisions

New guidebook helps patients and
caregivers cope with advanced cancer
Advances in the treatment of cancer have led to
improved cure rates and longer survival times, but
many cancer patients still die of their disease. When
the decision is made to end aggressive treatment
and focus instead on relieving symptoms, patients
and their caregivers must refocus the energy they
have spent fighting the cancer on meeting new
challenges.
A new guidebook published by the Supportive
Cancer Care Network at The University of Texas
M. D . Anderson Cancer Center is helping patients
and their caregivers cope with both the emotional
and the practical challenges of living with advanced cancer. A Caring Community: Guidebook
to Resources for Patients With Advanced Cancer
and Their Caregivers is the product of a two-year
effort led by Anthony Greisinger, M.A., Cancer
Prevention Project Specialist in the Department of
Neuro-Oncology.

Guidebook developed with help of patients
In 199 3, as part of the research for his doctoral
dissertation in behavioral science, Greisinger began interviewing terminally ill cancer patients and
their primary caregivers to identify their principal
concerns. The purpose of these interviews was to
gather information to develop a quality-of-life
questionnaire for patients with advanced cancer.
Greisinger interviewed patients at M. D. Anderson Cancer Center and the Hospice of the Texas
Medical Center and patients receiving home care
from the Hospice. At the outset of each interview,
he encouraged patients to talk about all areas of
their lives that had been affected by cancer.
-----------.., ome o
e patients a never een given t e
chance to talk about what they were going
through," said Greisinger. "Patients really opened
up and talked about the changes they had experienced as a result of the cancer. Many patients
wanted to know how their experiences compared
with those of other terminally ill patients-whether
what they were experiencing was normal." During
some of the interviews, Greisinger saw firsthand
how difficult it can be for patients with advanced
cancer to communicate with their families. "Sometimes the whole family would be in the room

during an interview, and the patient would ask me
'Do you think my family appreciates me? I'm not
sure if they love me. I wish they would talk to me
about the cancer but they won't."'
Greisinger also found that almost every patient
and family asked for information about supportive
care services. "Patients would ask me questions
like 'which legal documents do I need to complete?
how do we choose a hospice; we're scared-is it
like a hospital? how do I get transportation?' I was
collecting information to create the quality-of-life
scale, but this other need-for information about
supportive care services-became obvious."
Greisinger decided to develop a resource guide
to address patients' concerns and highlight the
services available to them in the community. "The
patients were so helpful to me," he said. "When
they realized that their participation in the study
could help other patients, they offered me so much
encouragement. I wanted to give something back
to them, and what I could do was to collect what
they had told me over the past year and put it
together in a book."
Together with Stephanie Teleki, a research assistant in the Department of Community Oncology, Greisinger contacted agencies in Harris
County to find out what specific services they
provide to patients with advanced cancer. With the
help of colleagues at M. D. Anderson, he wrote
several sections about coping with advanced cancer, incorporating many of the insights patients
had shared with him in over 200 interviews.
Throughout the development of the guidebook,
as he interviewed patients for his quality-of-life
stu y, reismger wou as
em to review ra s
and offer suggestions. When the project was near
completion, he did a pilot test to make sure that
the guidebook was easy for patients to use and that
it listed the information they needed. "It's really
the patients' book," said Greisinger. "It's a response to their needs and it is based on the insights
they gave me to share with other patients."

Supportive care

Anthony Greisinger is
Cancer Prevention Project
Specialist in the Department of Neuro-Oncology

Specific, helpful information
The guidebook is divided into two parts. Part I,
"Coping With Advanced Cancer," addresses
continued on page 4
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emotional concerns, family concerns, physical symptoms, pain control, relaxation techniques, sexuality and intimacy, spiritual concerns, sources of
hope, and living day to day. This section of the
guidebook describes some of the feelings that are
common among patients with advanced cancer
and offers many practical ideas for coping. Part II,
"Supportive Services in Harris County," is an annotated list of over 150 agencies that provide
services for terminally ill cancer patients, organized by type of service. Some of the areas covered
are home care services, nursing homes, hospice
care, food and nutrition, support groups and private counseling, grief and bereavement counseling, financial advice, and legal information. The
book gives the address and phone number of each
agency, along with information about specific services offered, eligibility, fees, and types of payment
accepted. Many sections include lists of questions
that patients might want to ask when seeking
assistance.
The guidebook also includes an annotated bibliography of books and publications about coping
with advanced cancer. One of the book's most
appealing features is the use of quotations from
patients. The quotations are set off in sidebars
throughout the guidebook.
To the best of his knowledge, said Greisinger,
A Caring Community is the only resource of its
kind. Although the National Cancer Institute, the
American Cancer Society, and many other organizations publish brochures on different aspects of
coping with cancer, no other publication combines information on coping with advanced cancer
with a comprehensive list of services for patients
with advanced cancer in Harris County. Greisinger
believes the comprehensive nature of the guidebook is a real benefit for patients. Instead of wading through a sea of brochures and pamphlets to
find the information they need, they can get it in
one compact book.
- -- - - - -- - - - ----1~-e-nts~--an-pla-y an activ~-ele4n--th-eir-ear~
"Many of the people I interview are unaware of
the services that are available or become aware of
them only in the last few weeks of life when they
need hospice care," said Greisinger. "My primary
goal is to make patients aware of what is available
in a more timely fashion." Once patients know
what is available, they can take a more active role
in their own care.
"Sometimes patients with advanced cancer feel
they're losing control of their lives," said Greisinger.
"They need help with everyday activities like buy-
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ing and preparing food, taking care of the house,
and getting to the hospital. I think the book may
make patients feel empowered. It helps them stay
actively involved in improving their own quality of
life."
And, viewed from another perspective, the book
helps patients stay actively involved in their community. Greisinger notes that patients with advanced cancer often feel isolated and cut off from
the rest of the world. He decided to title the
guidebook A Caring Community to emphasize
that even though patients have advanced cancer,
they are still valuable members .of a community
that cares about them.

Preparing for difficult decisions
When the time comes to plan for palliative care
and to face end-of-life issues, many patients and
their caregivers find it difficult to shift gears.
"Often I talk to patients just before they are discharged from the hospital," said Greisinger, "and
they'll say, 'We've spent the last five years fighting
the cancer, and now they're telling us we should
select a hospice, find a support group'-they're
just overwhelmed." Greisinger hopes the new
guidebook will alert patients to the decisions they
may have to make and allow them more time to
make those decisions.
In early 1996, M. D. Anderson discharge planning will become part of case management. Instead of working with a discharge planner right
before they are discharged from the hospital, patients will work with the same case manager from
the time of their first appointment through the
end of their cancer care. Annette Bisanz, R.N.,
clinical nurse specialist in the Practice Outcomes
Program, has been training the new case managers
in discharge planning and has been giving each of
them a copy of the book. She believes A Caring
Community will help patients and their families
prepare for tough decisions.
"This guidebook," she said, "in a nutshell, helps
patien-ts-faee-s-ome-ofthe-things-that-theynave--tcrmake decisions about. Even if the book just plants
some good ideas, that will be useful. There's nothing better than to work with an informed patient."
Case managers, according to Bisanz, will give
the book to patients and families when it appears
that the cancer is not curable but before the patient's
condition has deteriorated so much that he or she
is no longer able to actively participate in decision
making. That way, patients and their families will
have time to carefully consider and discuss their
options for such things as hospice or nursing home
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· care, support groups, medical equipment, transportation, and funeral planning and come to decisions based on the patient's wishes.

Future editions planned
The early response to the book has been positive. Within a month of the guidebook's initial
printing in October 1995, over 4,000 of the 5,000
first-edition copies had been distributed. Almost
every day, Greisinger receives requests for additional copies from agencies mentioned in the book
and from social workers at other institutions.
Suggestions from patients and from physicians,
nurses, and social workers will be incorporated
into a revised edition of the guidebook planned for
fall 1996. In the meantime, a second printing of
the first edition is planned for spring 1996 to meet
the demand for the book. Efforts are under way to
adapt the guidebook for use in seven other metropolitan areas across the United States.
Greisinger is presently conducting the final phase
ofinterviews for his quality-of-life study in advanced

Glioblastoma multiforme
conti nued fro m page 2

used first for gene therapy, adenoviruses appear to
have many advantages. Whereas retroviruses must
be permanently incorporated into each tumor cell's
genome to produce the desired gene, adenoviruses
can produce their proteins outside of the genome
and thus need only take up temporary residency in
the cell nucleus. Although the side effects of the
viruses themselves are believed to be minimal,
keeping the viral exposure brief reduces the risk of
unwanted cell transformation by the introduced
gene. The adenovirus can be inject
higher concentrations to the tumor, so it is not
necessary to insert it into carrier cells such as
fibroblasts. Moreover, whereas retrovirus can infect only dividing cells, adenovirus can infect either dividing or nondividing cells, thus killing
many more cells. This is especially critical in brain
tumors, in which fewer than 10% of the cells are
dividing at any moment.
Yung acknowledges that the fibroblast-retrovirus-gene construct is just a first step in the lengthy
process of developing an effective clinical treat-

cancer patients. If a patient is from Harris County,
Greisinger brings a copy of the guidebook to the
interview and asks the patient and his or her
caregivers to offer suggestions for future editions.
"The whole point of this project is to make the
guidebook useful for patients and their caregivers,"
said Greisinger, "and when you are there in the
room and they tell you that they needed something and they used the guidebook to find legal
assistance or hospice information, or you realize
that the guidebook helped them start to discuss a
sensitive issue, it's a great feeling."
-STEPHANIE P. DEMING
Readers who would like more information may write
Mr. Greisinger, Department of Neuro-Oncology, The
University of Texas M. D. Anderson Cancer Center,
Box 100, 1515 Holcombe Blvd., Houston, Texas 77030,
or call (713)792-7546. ■

ment. The next step is an improved delivery vehicle for the genetic construct-possibly adenovirus, possibly any of a number of other vehicles now
under development. A longer term goal is a gene
that can cure the cancer and a vehicle that can tell
the difference between cancer cells and normal
cells and infect only the cancer cells, "but we're
nowhere near that level of sophistication yet," said
Yung. "We have a large research program dedicated to finding a cure for glioblastoma multiforme, and we are one of the few clinical centers in
the country with a comprehensive approach to
these tumors. We are trying to find a way to give
more hope and more life to patients with these

"
-KATHRYN

L.

HALE

REFERRALS. Physicians who would like to refer patients or patients interested in self-referral may write Dr.
Yung at the Department ofNeuro-Oncology (Box 100)
or Dr. Sawaya at the Department ofNeurosurgery (Box
64), The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Blvd., Houston, Texas 77030,
or call (713)794-1285 (Dr. Yung) or (713)792-2400
(Dr. Sawaya). Physicians may also call the New Patient
Referral office at (713)792-6161 or (800)392-1611. ■
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Pituitary
continued from page 8

will meet a friend he has not seen for a while, years
maybe, and the friend will notice changes in the
person's appearance. His facial features may be
enlarged, for example. Quite often the changes
have occurred so slowly that the people who live
with the patient, his children or wife, will not have
noticed any change."
Other types of secretory tumors include adrenocorticotropic hormone (ACTH)-secreting tumors,
which can lead to Cushing's disease, and gonadotropin-secreting tumors, which can affect
fertility. The small ACTH-secreting tumors can
usually be detected only with highly sensitive screening. Gonadotropin-secreting tumors, on the other
hand, are large and are usually detected once they
impinge upon parts of the brain surrounding the
pituitary gland.

condition. For example, some symptoms of pituitary tumors mimic conditions related to diabetes,
hyperlipidemia, and even primary hyperthyroidism. In these cases, the pituitary tumor may be
diagnosed only after the onset of severe illness.
"The first challenge in managing pituitary tumors is confirming the diagnosis," said Keith E.
Friend, M.D., Endocrine Section, Department of
Medical Specialties. Because of the location of
pituitary tumors, advanced screening technologies
such as radioimmunological assays, computed tomography, and magnetic resonance imaging are
required to establish their biological makeup, exact position, and activity.
Some pituitary tumors never cause problems.
Treatment: weighing the benefits and risks
Of those that do, some secrete an excess of certain
Treatment presents the second challenge in the
hormones and others grow so large that they management of pituitary tumors. "Treatment recinhibit the normal function of the pituitary gland ommendations are based on the tumor's secretory
and impinge on other structures in the brain.
status and its size," said Friend. "We monitor
Ectopic hormone production by tumors in other some patients for several years, and unless horparts of the body can present an added challenge
mone secretion levels or tumor size becomes threatto diagnosing pituitary tumors. "Thorough endoening, treatment may not be required."
crinological investigation is needed to determine
There are two goals associated with the treatprecisely the type of tumor that has developed, and
ment of pituitary tumors. "The first," said Friend,
a series of biochemical tests are needed to deter"is to lower the hormonal secretion level to a
mine with certainty if the excess hormones are
normal state, preserving pituitary function and
being secreted from the pituitary gland or some reversing metabolic changes, such as abnormal
other source," Friend explained.
growth in the case of GR-producing tumors. The
Two of the more common types of secretory other goal is to shrink or remove the tumor before
tumors are prolactinomas, which secrete the horit begins to affect other parts of the brain. "
mone prolactin, and growth hormone ( GH)- Treatment options include medications, surgery,
secreting tumors. These tumors come to clinical radiotherapy, or a combination of surgery an d
attention because of their widespread physiologiradiotherapy.
cal and metabolic effects. Prolactinomas secrete
When treatment is required, consideration must
excess prolactin, disrupting reproductive functionagain be given to factors unique to pituitary tu ing in men and women. "Prolactinomas can stimumors. "The pituitary gland is connected to the
late the production of breast milk, cause abnormal hypothalamus via the pituitary stalk," said Friend.
menstrual cycles, and even lead to infertility," Friend "The risk that the treatment, particularly surgery
_____________., _.""'
sai""'d'-.'- - -"-'In"-"---"s=o,
""'
.m
. ,u.:e""----"'c=as..,_, e"'"'s_,_,+'pci....,raU,l....a~c.LJ.tiL.ln--'---'ot..L.JmLLa..J. _U,. .Lll.JLL\.L-LL.ll.µ:J.. LC---J--'-o~r------L-<ra:ud..Liil.-\..ot.l.r.w.bexaP-¥,Wi lL cause_fi.1-rther nemological
tence in men."
damage warrants consideration." Of primary conGrowth hormone-secreting tumors cause aero- sideration, although it is rare, is damage to the
megaly, which is characterized by enlargement of optic nerve because of its close proximity to the
distal parts of the body such as toes, fingers, feet, pituitary gland. "The clinician must decide if the
hands, nose, and ears. These tumors can also lead disabilities caused by the tumor are sufficient to
to arthritis and can increase the risk for gastrointes- warrant the potential side effects of the treattinal malignancies such as colon cancer. A comment."
mon symptom of GR-secreting tumors is increased
Bromocriptine has been used to treat prolactiring or shoe size. "These tumors are particularly nomas with a success rate of 80% to 90%. "The
insidious," Friend explained. "What frequently goal in treating this particular type of tumor is to
happens is that a person with one of these tumors inhibit the excess production of prolactin before
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the onset of osteoporosis," Friend reported.
Depending on th e size of the tumor, surgery may
be the first line of treatment for GR-producing
tumors; it has been effective in 50% of cases. "If
surgery does not cure, the patient may be given
octreotide or, in a small number of cases,
bromocriptine to regulate hormone production.
When medication s are prescribed for either prolactinomas or GB-producing tumors, they usually
must be taken for the rest of the patient's life.
Octreotide, for example, must be given by injection up to three times a day, although a longacting preparation is under development."
Treatment for pituitary tumors must be individualized to address specific symptoms and individual medical needs . "It is not uncommon for
tumors to produce more than one hormone in
excess. The most common combination is GH
and prolactin," explained Friend. So, the treatment chosen must be designed to adequately address both conditions. "In some cases, excess
production of one hormone severely reduces production of another hormone . A loss in production
of ACTH, for example, may lead to adrenal insufficiency, whereas a loss of gonadotropin hormones
can cause reproductive abnormalities. These scenarios must be taken into consideration when the
treatment is chosen."

Accuracy, expertise key in managing
pituitary tumors
Research on pituitary tumors is aimed at helping clinicians diagnose and treat these neoplasms.
For example, M. D. Anderson was recently involved in testing the efficacy of octreotide in the
treatment of GR-producing tumors. The cancer
center is also serving as a regional center for a
national acromegaly registry to evaluate various
treatments. Friend said that M. D. Anderson is
also directing interested patients to better prepare
them and their family members to make decisions
regarding care and to address the emotional and
psychological impacts of this disease. "Although
pituitary tumors are usually benign, they can cause
serious illness that deeply affects the patient's
lifestyle and well-being. Early diagnosis and a sound
treatment strategy are the keys to successful management of this disease."
-VICKIE

J.

WILLIAMS

REFERRALS. Readers who would like more information may write Dr. Friend, Endocrine Section, Department of Medical Specialties, Box 15, The University of
Texas M. D . Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, Texas 77030, or call (713 )792-2840.
Those interested in referrals may call Dr. Friend or the
New Patient Referral office, ( 713 ) 792-6161 or
(800)392-1611. ■
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Location makes pituitary tumors difficult to diagnose and treat

Benign pituitary tumors threaten
endocrine and nervous systems
Patient care

Keith E. Friend is assistant
professor in the Endocrine
Section, Department of
Medical Specialties

Pituitary tumors, which arise at the base of the
brain, account for up to 25% of all cancers within
the cranium. Because of their obscure location and
their slow growth, pituitary tumors present certain
diagnostic and treatment challenges. Many pituitary tumors go unnoticed for years, and quite
often they are discovered incidentally when the
ram is image or another reason. At oug pi uitary tumors are usually benign, often by the time
they are discovered they have caused severe hormonal imbalance or have invaded other parts of
the cranium, compressing or injuring vital structures. Either can be debilitating. However, early
detection, accurate diagnosis, and appropriate treatment can prevent this damage.
The University ofTexas M. D. Anderson Cancer
Center's approach to managing pituitary tumors is
to integrate expertise from many specialties,
including endocrinology, neuroradiology, neuro-

surgery, pathology, and radiotherapy. This multidisciplinary team can expedite diagnoses and determine the most appropriate treatment.
Many variables complicate diagnosis
The first signs of pituitary tumors may not
manifest for 10 years or more, but when they do
appear they can be severe. Patients with these
tumors may experience a wide range of complications, including headaches, visual disturbance,
sexual or reproductive dysfunction, and discomfort or disfigurement caused by the enlargement of
facial features and extremities. The exact complications will vary depending on the type of tumor and
the presence of other health problems. Even after
signs of the disease become a problem, they may
not cause immediate alarm in the patient or the
physician. Instead, the symptoms are often considered routine or isolated or are attributed to another
continued on page 6

